Invitae Stock Forecast, Price & News

Invitae (NYSE:NVTA) Frequently Asked Questions

Is Invitae a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Invitae stock.
View analyst ratings for Invitae or view top-rated stocks.

What stocks does MarketBeat like better than Invitae?

Wall Street analysts have given Invitae a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Invitae wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Invitae's next earnings date?

Invitae is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Invitae.

How were Invitae's earnings last quarter?

Invitae Co. (NYSE:NVTA) released its earnings results on Tuesday, August, 3rd. The medical research company reported ($0.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.65) by $0.20. The medical research company had revenue of $116.31 million for the quarter, compared to analyst estimates of $109.53 million. Invitae had a negative trailing twelve-month return on equity of 26.29% and a negative net margin of 149.68%.
View Invitae's earnings history.

How has Invitae's stock been impacted by Coronavirus?

Invitae's stock was trading at $15.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVTA shares have increased by 89.8% and is now trading at $30.08.
View which stocks have been most impacted by COVID-19.

What guidance has Invitae issued on next quarter's earnings?

Invitae issued an update on its FY 2021 earnings guidance on Tuesday, August, 24th. The company provided EPS guidance of for the period. The company issued revenue guidance of $475 million-$500 million, compared to the consensus revenue estimate of $463.25 million.

What price target have analysts set for NVTA?

9 analysts have issued 1-year price targets for Invitae's stock. Their forecasts range from $33.00 to $58.00. On average, they anticipate Invitae's stock price to reach $42.33 in the next twelve months. This suggests a possible upside of 40.7% from the stock's current price.
View analysts' price targets for Invitae or view top-rated stocks among Wall Street analysts.

Who are Invitae's key executives?

Invitae's management team includes the following people:

• Sean Emerson George, Chairman, President & Chief Executive Officer
• Kenneth D. Knight, Chief Operating Officer
• Roxi Wen, Chief Financial Officer
• Robert Nussbaum, Chief Medical Officer
• Layton Wedgeworth, Chief Technology Officer

What is Sean George's approval rating as Invitae's CEO?

59 employees have rated Invitae CEO Sean George on Glassdoor.com. Sean George has an approval rating of 87% among Invitae's employees.

Who are some of Invitae's key competitors?

Some companies that are related to Invitae include Quest Diagnostics (DGX), Guardant Health (GH), Natera (NTRA), Elekta AB (publ) (EKTAY), Veracyte (VCYT), CareDx (CDNA), Fulgent Genetics (FLGT), Burning Rock Biotech (BNR), Castle Biosciences (CSTL), RadNet (RDNT), Genetron (GTH), DermTech (DMTK), Personalis (PSNL), Renalytix AI (RNLX) and Sera Prognostics (SERA).
View all of NVTA's competitors.

What other stocks do shareholders of Invitae own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Square (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), The Trade Desk (TTD), Shopify (SHOP), salesforce.com (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

When did Invitae IPO?

(NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

What is Invitae's stock symbol?

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Who are Invitae's major shareholders?

Invitae's stock is owned by a number of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (10.71%), Vanguard Group Inc. (7.96%), Sumitomo Mitsui Trust Holdings Inc. (7.45%), Nikko Asset Management Americas Inc. (7.44%), Macquarie Group Ltd. (2.78%) and Perceptive Advisors LLC (2.22%). Company insiders that own Invitae stock include Artur Bergman, E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert L Nussbaum, Sean E George, Sean E George, Shelly D Guyer and Thomas Brida.
View institutional ownership trends for Invitae.

Which institutional investors are selling Invitae stock?

NVTA stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Perceptive Advisors LLC, Perceptive Advisors LLC, Citadel Advisors LLC, Wells Fargo & Company MN, Compagnie Lombard Odier SCmA, Redmile Group LLC, and Ikarian Capital LLC. Company insiders that have sold Invitae company stock in the last year include Artur Bergman, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert L Nussbaum, Sean E George, Shelly D Guyer, and Thomas Brida.
View insider buying and selling activity for Invitae or view top insider-selling stocks.

Which institutional investors are buying Invitae stock?

NVTA stock was acquired by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Light Street Capital Management LLC, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Goldman Sachs Group Inc., Geode Capital Management LLC, Alyeska Investment Group L.P., and Northern Trust Corp.
View insider buying and selling activity for Invitae or or view top insider-buying stocks.

How do I buy shares of Invitae?

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Invitae's stock price today?

One share of NVTA stock can currently be purchased for approximately $30.08.

How much money does Invitae make?

Invitae has a market capitalization of $6.54 billion and generates $279.60 million in revenue each year. The medical research company earns $-602,170,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis.

How many employees does Invitae have?

Invitae employs 2,100 workers across the globe.

What is Invitae's official website?

The official website for Invitae is www.invitae.com.

Where are Invitae's headquarters?

Invitae is headquartered at 1400 16th Street, SAN FRANCISCO CA, 94103.

How can I contact Invitae?

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at (415) 374-7782 or via email at [email protected].